Device Trial Radar · NCT02539069
The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Oct 23, 2012
Primary completion
Jan 15, 2016
Study completion Jan 15, 2016
Sponsor
- Lead sponsor
- Cellontech Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 2, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical trial to evaluate the long-term efficacy and safety of Chondron (Autologous cultured Chondrocyte) administered through arthroscopy from the drug's 48 weeks efficacy and safety evaluation with 96 weeks follow-up in patients with knee cartilage defects.
Conditions
- Osteoarthritis
- Traumatic Arthritis
Interventions
Chondron ImplantationDevice
In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in pain of 100mm Visual Analog ScaleTime frame: 48 weeks after the surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yonsei University Severance Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.